Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess

Introduction: Tumor necrosis factor (TNF) inhibitors (adalimumab, infliximab, etanercept, golimumab, and certolizumab pegol) have revolutionized the treatment of severe immune-mediated inflammatory diseases, including rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mingming, You, Ruxu, Su, Yuyong, Zhou, Hongbo, Gong, Shiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404848/
https://www.ncbi.nlm.nih.gov/pubmed/37554981
http://dx.doi.org/10.3389/fphar.2023.1169327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404848/
https://www.ncbi.nlm.nih.gov/pubmed/37554981
http://dx.doi.org/10.3389/fphar.2023.1169327

Ejemplares similares